

Black Box Warnings	Last update	SERIOUS INFECTIONS	MORTALITY	MALIGNANCY	THROMBOSIS
Xeljanz (tofacitinib)	2019	serious infections leading to hospitalization or death. including tuberculosis,bacterial, fungal, viral and other.	Yes	Lymphoma and other malignancies (including Epstein Barr)	RA patients with a CV risk factor had a higher death rate and thrombosis rate with Xeljanz high dose 10mg.
Oluminant (baricitinib)	2018	serious infections leading to hospitalization or death including tuberculosis,bacterial, fungal, viral and other.	No	Lymphoma and other malignancies	DVT/PE (thrombosis). Thrombosis, including DVT, PE and arterial thrombosis, some fatal.
Rinvoq (upadacitinib)	2019	serious infections leading to hospitalization or death including tuberculosis,bacterial, fungal (including cryptococcosis and pneumocystosis), viral (including herpes zoster) and other.	No	Lymphoma and other malignancies	DVT/PE (thrombosis). Thrombosis, including DVT, PE and arterial thrombosis, some fatal, in patients with JAK inhibitors
Humira (adalimumab)	2018	serious infections leading to hospitalization or death including tuberculosis,bacterial, fungal (including histoplasmosis), and other	No	Lymphoma and other malignancies. HSTCL added post-markteting	No
Filgotinib (not approved yet)	2020?	Probably: 1,4%, lower than other JAKs and Humira, but more than placebo (1%)	No	Probably not: lower than placebo	Probably not: equal or lower than placebo